Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.

Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L

Anticancer research1 Mar 2002Cited by 56 (Europe PMC)

PMID12168923PepBankPUB-12168923

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In terminal cancer with bowel obstruction, octreotide and hyoscine groups differed in vomiting change from baseline to the third treatment day (p<0.05).
In plain wordsIn terminal cancer with bowel obstruction, vomiting change differed between octreotide and hyoscine groups; the result does not state its direction.
Peptide
Octreotide
Outcome
Direction not reportedVomiting percentage change
Study
n = 68
Comparator
Hyoscine butylbromide with shared chlorpromazine
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
600-800 microg/day · continuous subcutaneousAs given in this study (human).
Source sentences
Summary
Data analysis showed there were statistically significant differences between the two groups: a) in vomiting and nausea in relation to percentage change from T1 to T2 and b) in fatigue and anorexia in relation to symptom improvement at T1 to T2, T1 to T3 and T1 to T4 (p<0.05),
3 context sentences(design, population, supporting numbers)
Summary · context
The symptoms were assessed at T1-baseline, T2 and T3-third and sixth day of treatment, respectively, and T4- one day before death.
Summary · context
The patients were randomly assigned into two equal groups, A (N=34) and B (N=34).
Summary · context
Group A received, by continuous subcutaneous (c.sc.) administration with a pump: hyoscine butylbromide 60-80mg/day and chlorpromazine (15-25 mg/day); group B received octreotide 600-800 microg/day and chlorpromazine (15-25 mg/day).
Report a problemFND-1216892301
02HumanRandomized controlled trialEfficacy outcome
In terminal cancer with bowel obstruction, octreotide and hyoscine groups differed in nausea change from baseline to the third treatment day (p<0.05).
In plain wordsIn terminal cancer with bowel obstruction, nausea change differed between octreotide and hyoscine groups; the result does not state its direction.
Peptide
Octreotide
Outcome
Direction not reportedNausea percentage change
Study
n = 68
Comparator
Hyoscine butylbromide with shared chlorpromazine
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
600-800 microg/day · continuous subcutaneousAs given in this study (human).
Source sentences
Summary
Data analysis showed there were statistically significant differences between the two groups: a) in vomiting and nausea in relation to percentage change from T1 to T2 and b) in fatigue and anorexia in relation to symptom improvement at T1 to T2, T1 to T3 and T1 to T4 (p<0.05),
3 context sentences(design, population, supporting numbers)
Summary · context
The symptoms were assessed at T1-baseline, T2 and T3-third and sixth day of treatment, respectively, and T4- one day before death.
Summary · context
The patients were randomly assigned into two equal groups, A (N=34) and B (N=34).
Summary · context
Group A received, by continuous subcutaneous (c.sc.) administration with a pump: hyoscine butylbromide 60-80mg/day and chlorpromazine (15-25 mg/day); group B received octreotide 600-800 microg/day and chlorpromazine (15-25 mg/day).
Report a problemFND-1216892302
03HumanRandomized controlled trialEfficacy outcome
In terminal cancer with bowel obstruction, fatigue improvement differed between octreotide and hyoscine groups at T2, T3, and T4 (p<0.05).
In plain wordsIn terminal cancer with bowel obstruction, fatigue improvement differed between octreotide and hyoscine groups at the reported assessments.
Peptide
Octreotide
Outcome
Direction not reportedFatigue improvement
Study
n = 68
Comparator
Hyoscine butylbromide with shared chlorpromazine
Outcome group
Exercise and physical function · Whole body
Studied dose
600-800 microg/day · continuous subcutaneousAs given in this study (human).
Source sentences
Summary
Data analysis showed there were statistically significant differences between the two groups: a) in vomiting and nausea in relation to percentage change from T1 to T2 and b) in fatigue and anorexia in relation to symptom improvement at T1 to T2, T1 to T3 and T1 to T4 (p<0.05),
2 context sentences(design, population, supporting numbers)
Summary · context
The patients were randomly assigned into two equal groups, A (N=34) and B (N=34).
Summary · context
Group A received, by continuous subcutaneous (c.sc.) administration with a pump: hyoscine butylbromide 60-80mg/day and chlorpromazine (15-25 mg/day); group B received octreotide 600-800 microg/day and chlorpromazine (15-25 mg/day).
Report a problemFND-1216892303
04HumanRandomized controlled trialEfficacy outcome
In terminal cancer with bowel obstruction, anorexia improvement differed between octreotide and hyoscine groups at T2, T3, and T4 (p<0.05).
In plain wordsIn terminal cancer with bowel obstruction, appetite symptom improvement differed between octreotide and hyoscine groups at the reported assessments.
Peptide
Octreotide
Outcome
Direction not reportedAnorexia improvement
Study
n = 68
Comparator
Hyoscine butylbromide with shared chlorpromazine
Outcome group
Appetite and food intake · Gastrointestinal
Studied dose
600-800 microg/day · continuous subcutaneousAs given in this study (human).
Source sentences
Summary
Data analysis showed there were statistically significant differences between the two groups: a) in vomiting and nausea in relation to percentage change from T1 to T2 and b) in fatigue and anorexia in relation to symptom improvement at T1 to T2, T1 to T3 and T1 to T4 (p<0.05),
2 context sentences(design, population, supporting numbers)
Summary · context
The patients were randomly assigned into two equal groups, A (N=34) and B (N=34).
Summary · context
Group A received, by continuous subcutaneous (c.sc.) administration with a pump: hyoscine butylbromide 60-80mg/day and chlorpromazine (15-25 mg/day); group B received octreotide 600-800 microg/day and chlorpromazine (15-25 mg/day).
Report a problemFND-1216892304
05HumanRandomized controlled trialEfficacy outcome
In terminal cancer with bowel obstruction, pain change did not differ significantly between octreotide and hyoscine groups at T2, T3, and T4.
In plain wordsIn terminal cancer with bowel obstruction, pain change did not differ significantly between octreotide and hyoscine groups.
Peptide
Octreotide
Outcome
No significant changePain percentage change
Study
n = 68
Comparator
Hyoscine butylbromide with shared chlorpromazine
Outcome group
Pain · Gastrointestinal
Studied dose
600-800 microg/day · continuous subcutaneousAs given in this study (human).
Source sentences
Summary
while in pain there was no statistically significant difference between the two groups in relation to percentage change from T1 to T2, T1 to T3 and T1 to T4.
2 context sentences(design, population, supporting numbers)
Summary · context
The patients were randomly assigned into two equal groups, A (N=34) and B (N=34).
Summary · context
Group A received, by continuous subcutaneous (c.sc.) administration with a pump: hyoscine butylbromide 60-80mg/day and chlorpromazine (15-25 mg/day); group B received octreotide 600-800 microg/day and chlorpromazine (15-25 mg/day).
Report a problemFND-1216892305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.